Skip to main content

Table 5 Association of therapeutic response and pulmonary function change

From: Therapeutic effect of budesonide/formoterol, montelukast and N-acetylcysteine for bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation

  No-response group Response group P-value
BOS diagnosis
 FVC (% predicted) 72.27 ± 15.42 73.19 ± 12.87 .838
 FEV1 (% predicted) 56.46 ± 16.05 56.73 ± 15.52 .959
 FEV1/FVC (%) 63.64 ± 10.54 63.83 ± 16.29 .970
 RV (% predicted) 103.50 ± 39.10 116.68 ± 35.88 .307
 TLC (% predicted) 82.30 ± 11.58 90.57 ± 12.07 .054
 RV/TLC (%) 37.80 ± 10.76 40.93 ± 9.59 .366
 DLCO (% predicted) 58.40 ± 21.81 63.30 ± 16.49 .429
Pre-HSCT – BOS diagnosisa
 Δ FVC (% predicted) 12.45 ± 13.28 23.59 ± 15.88 .036
 Δ FEV1 (% predicted) 30.81 ± 18.16 40.61 ± 18.89 .126
 Δ FEV1/FVC (%) 18.18 ± 12.78 14.46 ± 15.63 .467
 Δ RV (% predicted) −20.20 ± 32.45 −36.63 ± 35.90 .194
 Δ TLC (% predicted) 3.90 ± 13.85 3.63 ± 11.25 .948
 Δ RV/TLC (%) −9.90 ± 7.69 −14.08 ± 10.17 .232
 Δ DLCO (% predicted) −1.00 ± 20.75 −0.51 ± 16.73 .937
  1. aFour missing values in Pre-HSCT (N = 57). Data represent the mean ± SD. P-values shown in bold are significant at the 0.05 level. HSCT hematopoietic stem cell transplantation, BOS bronchiolitis obliterans syndrome, FVC forced vital capacity, FEV1 forced expiratory volume in 1s, RV residual volume, TLC total lung capacity, DLCO carbon monoxide diffusion in the lung